Skip to search formSkip to main content
You are currently offline. Some features of the site may not work correctly.

LAF 237

Known as: LAF-237, LAF237 
 
National Institutes of Health

Papers overview

Semantic Scholar uses AI to extract papers important to this topic.
Highly Cited
2012
Highly Cited
2012
Dipeptidyl peptidase (DPP) IV inhibitors are probably beneficial for preventing diabetic complication and modulating glucagon… Expand
  • table 1
  • table 2
  • figure 1
  • figure 2
  • figure 3
Is this relevant?
2012
2012
Aim. To investigate the combination effects and mechanisms of valsartan (angiotensin II type 1 receptor blocker) and LAF237 (DPP… Expand
  • figure 1
  • table 1
  • figure 2
  • figure 3
  • figure 4
Is this relevant?
Highly Cited
2011
Highly Cited
2011
Fibroblast activation protein-α (FAP) is a cell surface, serine protease of the post-prolyl peptidase family that is expressed in… Expand
  • figure 1
  • figure 2
  • figure 3
  • figure 4
  • figure 5
Is this relevant?
2008
2008
LAF237 [(S)-1-[(3-hydroxy-1-adamantyl)ammo]acetyl-2-cyanopyrrolidine] is an inhibitor of dipeptidyl peptidase IV that delays the… Expand
Is this relevant?
2007
2007
Thiazolidinediones (TZDs) are currently the most efficacious class of oral antidiabetics. However, they carry the burden of… Expand
Is this relevant?
Highly Cited
2005
Highly Cited
2005
OBJECTIVE A novel treatment option for diabetic patients is the enhancement of incretin hormone activity by inhibition of the… Expand
Is this relevant?
2005
2005
Background LAF237 is a selective DPP-4 inhibitor under development as an anti-diabetic agents. The objective of this study was… Expand
Is this relevant?
Highly Cited
2004
Highly Cited
2004
This study characterizes the high-fat diet-fed mouse as a model for impaired glucose tolerance (IGT) and type 2 diabetes. Female… Expand
  • figure 1
  • figure 3
  • figure 2
Is this relevant?
Highly Cited
2004
Highly Cited
2004
The stimulation of insulin vs. inhibition of glucagon secretion in relation to the antidiabetic action of glucagon-like peptide-1… Expand
  • figure 1
  • table 1
  • table 2
  • figure 2
  • figure 3
Is this relevant?
Highly Cited
2004
Highly Cited
2004
OBJECTIVE To assess the 12- and 52-week efficacy of the dipeptidyl peptidase IV inhibitor LAF237 versus placebo in patients with… Expand
  • table 1
  • figure 1
  • figure 2
  • table 2
Is this relevant?